Merck & Company, Inc. vs Intellia Therapeutics, Inc. — Stock Comparison

MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
vs
NTLA
Intellia Therapeutics, Inc.
$13.26
▼ 1.63%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 6.2/10

Q·Score Breakdown

6.7
Neutral
Overall
6.2
Neutral
6.2
Quality
1.6
7
Health
9.7
6.2
Growth
7.8
7.2
Valuation
6.9
7.1
Sentiment
6.4
MRK

Forward P/E of 11.5× is low relative to sector peers.

NTLA

Clean balance sheet with low leverage (0.1× debt-to-equity).

low return on equity (-53%).

Analyst Consensus

BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $26.71 (+101.5%)
21 analysts

Fundamentals

MRK
NTLA
31.5×
Trailing P/E
11.5×
Forward P/E
-4.6×
13.6%
Profit Margin
0.0%
76.6%
Gross Margin
0.0%
ROE
-53.5%
4.9%
Revenue Growth
78.8%
Earnings Growth
0.28
Beta
1.99
Price / Book
$277.0B
Market Cap
$1.6B
$73 – $125
52-Week Range
$7 – $28

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →